XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XLO XILIO THERAPEUTICS, INC.

已收盘 01-21 16:00:00 EST

0.5971

-0.0289

-4.62%

盘后0.5976

+0.0005+0.08%

19:36 EST

最高0.6340	最低0.5900	成交量60.02万
今开0.6300	昨收0.6260	日振幅7.03%
总市值4,033万	流通市值2,176万	总股本6,754万
成交额36.61万	换手率1.65%	流通股本3,644万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XLO","market":"US","secType":"STK","nameCN":"XILIO THERAPEUTICS, INC.","latestPrice":0.5971,"timestamp":1769029200000,"preClose":0.626,"halted":0,"volume":600201,"hourTrading":{"tag":"盘后","latestPrice":0.5976,"preClose":0.5971,"latestTime":"19:36 EST","volume":3476,"amount":2088.2374,"timestamp":1769042211353,"change":0.0005,"changeRate":0.000837,"amplitude":0.051918},"delay":0,"changeRate":-0.046166134185303576,"floatShares":36436400,"shares":67540900,"eps":-0.61,"marketStatus":"已收盘","change":-0.0289,"latestTime":"01-21 16:00:00 EST","open":0.63,"high":0.63399,"low":0.59,"amount":366130.8327537,"amplitude":0.070272,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.61,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1769072400000},"marketStatusCode":5,"adr":0,"listingDate":1634875200000,"exchange":"NASDAQ","adjPreClose":0.626,"preHourTrading":{"tag":"盘前","latestPrice":0.6139,"preClose":0.626,"latestTime":"09:25 EST","volume":1615,"amount":1007.2218819999999,"timestamp":1769005521428,"change":-0.0121,"changeRate":-0.019329,"amplitude":0.087859},"postHourTrading":{"tag":"盘后","latestPrice":0.5976,"preClose":0.5971,"latestTime":"19:36 EST","volume":3476,"amount":2088.2374,"timestamp":1769042211353,"change":0.0005,"changeRate":0.000837,"amplitude":0.051918},"volumeRatio":1.958202},"requestUrl":"/m/hq/s/XLO","defaultTab":"news","newsList":[{"id":"1162973781","title":"Xilio Therapeutics第三季度净收入为-1628.7万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162973781","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162973781?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:40","pubTimestamp":1763574028,"startTime":"0","endTime":"0","summary":"11月13日 - Xilio Therapeutics第三季度营业收入为-192.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"1158166179","title":"Xilio Therapeutics 发布关于Vilastobart的晚期第二阶段数据，适用于MSS mCRC及高血浆肿瘤突变负担患者，在免疫治疗癌症学会(SITC)40周年年会上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1158166179","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158166179?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572105,"startTime":"0","endTime":"0","summary":"11月7日（路透社） - Xilio Therapeutics Inc：*XILIO THERAPEUTICS 发布关于Vilastobart的晚期第二阶段数据，适用于MSS mCRC及高血浆肿瘤突变负担患者，在免疫治疗癌症学会（SITC）第40届年会上公布。这些信息源自于发表于2025年11月7日14:05:00.14 GMT的路透社投资者简报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"1122495686","title":"Xilio Therapeutics发布Vilastobart在MSS MCRC及高血浆肿瘤突变负荷患者中的最新第二阶段数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1122495686","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122495686?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:06","pubTimestamp":1762524375,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics发布Vilastobart在MSS MCRC及高血浆肿瘤突变负荷患者中的最新第二阶段数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"1115293544","title":"Xilio Therapeutics宣布将在癌症免疫治疗学会(SITC)第40届年会上进行演讲展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1115293544","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115293544?lang=zh_cn&edition=full","pubTime":"2025-10-03 21:01","pubTimestamp":1759496475,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics宣布将在癌症免疫治疗学会(SITC)第40届年会上进行演讲展示","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"1156903261","title":"Xilio Therapeutics普通股转移至纳斯达克资本市场，10月6日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1156903261","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156903261?lang=zh_cn&edition=full","pubTime":"2025-10-03 19:35","pubTimestamp":1759491331,"startTime":"0","endTime":"0","summary":"根据SEC文件显示，Xilio Therapeutics将其普通股上市地点转移至纳斯达克资本市场，该变更将于10月6日生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"1148445703","title":"Xilio Therapeutics宣布启动肿瘤激活IL-12药物Efarindodekin Alfa (Xtx301)的二期试验，并在与Gilead的独家许可协议下达成1750万美元开发里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1148445703","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148445703?lang=zh_cn&edition=full","pubTime":"2025-09-09 19:31","pubTimestamp":1757417483,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics宣布启动肿瘤激活IL-12药物Efarindodekin Alfa (Xtx301)的二期试验，并在与Gilead的独家许可协议下达成1750万美元开发里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2510377483","title":"Xilio Therapeutics(XLO)盘前涨超114% 与艾伯维达成合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2510377483","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510377483?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:10","pubTimestamp":1739369403,"startTime":"0","endTime":"0","summary":"金吾财讯 | Xilio Therapeutics(XLO)盘前涨超114%，报1.42美元。消息面上，艾伯维公司与Xilio Therapeutics签署了一份潜在价值超过20亿的合作和许可选择协议，旨在为Xilio提供支持。两家公司将共同开发新的肿瘤激活抗体免疫疗法。Xilio将获得5200万美元的预付款，还将有资格获得额外的21亿美元，以覆盖与选择相关的费用和里程碑以及产品销售的版税。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"285376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xiliotx.com","stockEarnings":[{"period":"1week","weight":-0.0454},{"period":"1month","weight":-0.0643},{"period":"3month","weight":-0.1684},{"period":"6month","weight":-0.0929},{"period":"1year","weight":-0.4509},{"period":"ytd","weight":-0.0222}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Xilio Therapeutics, Inc.于2020年6月18日在特拉华州注册成立。该公司是一家生物技术公司，专注于利用免疫系统实现深度和持久的临床反应，以改善癌症患者的生活。该公司已经建立了地理上精确的解决方案，或GPS平台，以快速设计新的分子，包括细胞因子和生物制剂，这些分子旨在通过地理上定位其在肿瘤内的活动来优化其治疗指数。该公司正在通过不同的发展阶段推进一些地理上精确的或肿瘤选择性的药物。该公司还计划继续利用他们的GPS平台开发更多的免疫疗法，包括具有一系列肿瘤靶向方法的候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.021072},{"month":2,"riseRate":0.5,"avgChangeRate":0.057614},{"month":3,"riseRate":0.25,"avgChangeRate":-0.049721},{"month":4,"riseRate":0.5,"avgChangeRate":-0.109931},{"month":5,"riseRate":0.5,"avgChangeRate":0.052494},{"month":6,"riseRate":0,"avgChangeRate":-0.163729},{"month":7,"riseRate":0.5,"avgChangeRate":0.01036},{"month":8,"riseRate":0.5,"avgChangeRate":-0.060444},{"month":9,"riseRate":0.5,"avgChangeRate":0.039039},{"month":10,"riseRate":0.5,"avgChangeRate":0.099935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.160439},{"month":12,"riseRate":0.4,"avgChangeRate":-0.10922}],"exchange":"NASDAQ","name":"XILIO THERAPEUTICS, INC.","nameEN":"XILIO THERAPEUTICS, INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供XILIO THERAPEUTICS, INC.(XLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"XILIO THERAPEUTICS, INC.,XLO,XILIO THERAPEUTICS, INC.股票,XILIO THERAPEUTICS, INC.股票老虎,XILIO THERAPEUTICS, INC.股票老虎国际,XILIO THERAPEUTICS, INC.行情,XILIO THERAPEUTICS, INC.股票行情,XILIO THERAPEUTICS, INC.股价,XILIO THERAPEUTICS, INC.股市,XILIO THERAPEUTICS, INC.股票价格,XILIO THERAPEUTICS, INC.股票交易,XILIO THERAPEUTICS, INC.股票购买,XILIO THERAPEUTICS, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供XILIO THERAPEUTICS, INC.(XLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}